Clinical trialsRegistry-verified

NeuroClin Glasgow

Glasgow

Treatment & access

Treatments offeredLSD (MM120 — clinical trial)
Access routeTrial
Cost & coverage (registry status)Free within clinical trial
Websitehttps://neuroclin.com

About this provider

Compiled from the registry data on this page.

NeuroClin Glasgow in Glasgow, United Kingdom, is listed as a site of the Panorama study, a Phase 3 clinical trial of MM120 (lysergide, a pharmaceutical form of LSD) in generalized anxiety disorder, registered on ClinicalTrials.gov under NCT06809595, the registry source cited by this record. As of 2026-08-07 the registry lists the study as ACTIVE_NOT_RECRUITING: recruitment has closed and new participants can no longer join at this site. Within the trial, treatment is free of charge for enrolled participants. The record was last verified on 2026-08-07.

Verification

At least one source for this record is a public state registry or an official public-law register. The registry entry is linked below and re-checked at least every 90 days.

License / registryPublic trial registry (ClinicalTrials.gov / EU CTIS)
Official registryhttps://clinicaltrials.gov/study/NCT06809595
Provider websitehttps://neuroclin.com
Last verified2026-08-07

Spotted an error? See our methodology for how records are checked and how to report a correction.

Check your fit & enquire

Clinical trials access follows published criteria. A short pre-screening comes first — then your compiled summary goes to NeuroClin Glasgow only with your explicit consent, and you can download it for yourself either way.

Check my fit & enquire

About two minutes. The check itself runs in your browser — your answers are never sent anywhere unless you choose to send them. We count only anonymous usage events.

Check my fit & enquire